PICO Portalanswers from OpenAlex & ORCID
Jerome B. Zeldis
ResearcherPublications, citations & collaboration network
Jerome B. Zeldis is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Jerome B. Zeldis have?
PICO Portalindexed works
Jerome B. Zeldis has 250 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jerome B. Zeldis have?
PICO Portalcitation count
Jerome B. Zeldis has 21,844 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Jerome B. Zeldis?
PICO Portalh-index
Jerome B. Zeldis has an h-index of 66 in OpenAlex.
What is the i10-index of Jerome B. Zeldis?
PICO Portali10-index
Jerome B. Zeldis has an i10-index of 153 in OpenAlex.
What is the ORCID of Jerome B. Zeldis?
PICO Portalorcid
The ORCID for Jerome B. Zeldis is on the source record.
What is the OpenAlex record for Jerome B. Zeldis?
PICO Portalopenalex
The OpenAlex for Jerome B. Zeldis is on the source record.
What are the most-cited papers on Jerome B. Zeldis?
PICO Portalmost cited works
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Seema Singhal, Jayesh Mehta, Raman Desikan, Dan Ayers, Paula K. Roberson, Paul Eddlemon, Nikhil C. Munshi, Elias Anaissie, Carla S. Wilson, Madhav V. Dhodapkar, Jerome B. Zeldis, David S. Siegel, John Crowley, Bart Barlogie
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Paul G. Richardson, Robert Schlossman, Edie Weller, Teru Hideshima, Constantine S. Mitsiades, Faith E. Davies, Richard LeBlanc, Laurence Catley, Deborah Doss, Kathleen Kelly, Mary McKenney, Julie Mechlowicz, Andrea Freeman, Reggie Deocampo, Rebecca L. Rich, Joan J. Ryoo, Dharminder Chauhan, Kathe Balinski, Jerome B. Zeldis, Kenneth C. Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust, Melissa Alsina, Robert Schlossman, S. Vincent Rajkumar, K.R. Desikan, Teru Hideshima, Nikhil C. Munshi, Kathleen Kelly-Colson, Deborah Doss, Mary McKenney, Svetlana G. Gorelik, Diane Warren, Andrea Freeman, Rebecca L. Rich, Anfang Wu, Marta Olesnyckyj, Kenton Wride, William S. Dalton, Jerome B. Zeldis, Robert Knight, Edie Weller, Kenneth C. Anderson
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera